Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)
Clinical trial NCT02249221 · COMPLETED
Trial details
- NCT number
- NCT02249221
- Sponsor
- Green Cross Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2014-11-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.